Pfizer CentreOne appoints new General Manager Andrew Moore
Pfizer CentreOne, a global pharmaceutical contract development and manufacturing organization (CDMO) embedded within Pfizer and a leading supplier of specialty APIs, today announced the appointment of Andrew Moore as general manager. This follows the outgoing general manager, JoyL Silva’s transition to Vice President, Global Franchise Lead for Hematology and Commercial Excellence within Pfizer’s Oncology Division.
Andrew is an experienced healthcare leader, innovator and entrepreneur, who began his healthcare career in sales and marketing, including seven years at Pfizer. He has also held leadership roles at AmerisourceBergen and McKesson.
Most recently Andrew was the CEO of CogxVision, a Carnegie Mellon University start-up company that applies artificial intelligence and machine learning to improve safety, outcomes, asset management and selling performance for the healthcare industry.
Prior to his professional career, Andrew served in the U.S. Army where he received multiple accolades, including the Bronze Star for his combat experience in Iraq Desert Storm. Andrew holds an undergraduate degree from University of Southern Mississippi and participated in a MSBA graduate candidate degree program at Boston University in Heidelberg, Germany.
As the general manager of Pfizer CentreOne, Andrew will spearhead the CDMO’s growth plans in the contract manufacturing sector with a focus on leveraging Pfizer’s extensive development and manufacturing capabilities in small molecule API, large molecule biologics, sterile injectables and oral solids. Additionally, he will continue to cement Pfizer CentreOne’s position as a leading supplier of quality steroid and hormone APIs and intermediates.
“Having previously worked for Pfizer, I am looking forward to leading Pfizer CentreOne to be the CDMO partner of choice,” said Moore.
“JoyLSilva has helped grow Pfizer CentreOne with a clear strategy complementary to Pfizer’s business model. I’m honored and excited to drive the next phase of our growth.”
“As a CDMO embedded within a global biopharmaceutical company, we are able to draw upon Pfizer’s vast resources and are uniquely positioned to understand the challenges and regulatory hurdles faced by our customers. This unique value proposition sets us apart in a crowded marketplace.”
“I look forward to bringing a new perspective and an innovative mindset to the role, garnered from my most recent experience of leading a start-up company.”